REGN2810

Phase 2Small molecule

Regeneron

REGN2810 is one of 65 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Prostate CancerActive, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 3

17 2

Benadryl

PParkedale

Phase 3

2 3

QL1706

Qilu Pharmaceutical Co., Ltd.

Phase 3

3 4

Consolidative Therapy

SSun Yat-sen University

Phase 3

2 5

REGN2810

Regeneron

Phase 2

6 6

Remeron

OOrganon and Co

Preclinical

1 7

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Active, not recruiting

Advanced Non-Small Cell Lung Cancer

NCT06269133

Q2 2028

Phase 2Active, not recruiting

Prostate Cancer

NCT03951831

Clinical

Trials by Indication[1]

Head and Neck Cancer1 trial

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)

Completed· Regeneron logo

Regeneron·Phase 1·NCT03198130·33 enrolled

Prostate Cancer1 trial

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

Active, not recruiting·MMark Stein·Phase 2·NCT03951831·26 enrolled

PD-11 trial

Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

Withdrawn· Regeneron logo

Regeneron·Phase 1·NCT02520245

Lung Cancer1 trial

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Completed· Regeneron logo

Regeneron·Phase 3·NCT03409614·790 enrolled

Melanoma1 trial

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)

Completed· Regeneron logo

Regeneron·Phase 1·NCT03002376·47 enrolled

1 more indication

Advanced Non-Small Cell Lung Cancer1 trial

Evaluating the Safety and Effectiveness of Cemiplimab in Combination With Platinum-Doublet Chemotherapy by Demographic Characteristics in First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Multi-Database Real World Evidence Study in US Patients

Active, not recruiting· Regeneron logo

Regeneron··NCT06269133·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for REGN2810. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REGN2810 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REGN2810. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Regeneron

REGN2810

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2028

Trials by Indication[1]

Head and Neck Cancer1 trial

Prostate Cancer1 trial

PD-11 trial

Lung Cancer1 trial

Melanoma1 trial

Advanced Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News